Jump to section
About this journal
Aims and scope
The field of immunotherapy is moving forward at an unprecedented rate, and a range of therapeutic approaches are now used in clinical practice, often with outstanding success. Cancer immunotherapies are coming of age and have the potential to produce long-lasting remission, often with fewer side effects and reduced drug resistance compared with conventional therapies. Recently the FDA has approved immunotherapies for melanoma and lung cancer, and clinical trials are yielding positive results for a range of cancer types, reflecting the promising new role for immunotherapy in cancer treatment. Immunotherapies are also being applied in a variety of other disease areas, including allergy, rheumatoid disease, autoimmunity and transplantation, as well as in many infections, such as HIV and hepatitis.
Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field.
Articles published in Immunotherapy include key areas such as:
- Cancer immunotherapy, including checkpoint blockade, cancer vaccines, adoptive T cell therapy, monoclonal antibodies and cytokines
- Combined chemo/radio immunotherapy in cancer treatment
- Biomarkers for personalized cancer immunotherapy
- Allergen immunotherapy, including sublingual, subcutaneous and oral immunotherapy
- Restorative immunotherapy for HIV and other immunocompromised patients
- Suppressive immunotherapy for autoimmunity diseases and transplantation
- Basic science of immunotherapeutic approaches
- Drug–immune system interactions
- Drug delivery systems, drug combinations and drug–drug interactions
- Summaries evaluating newly approved immunotherapeutic agents
- Newly identified immune targets of drugs
- Results of recent findings and clinical trials relevant to the field of immunotherapy
- Post marketing research, including adverse events, drug safety, pharmacoeconomics, cost–benefit issues, real-world evidence and outcomes research
Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal's Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.
Journal metrics
Citation metrics
- 2.7 (2023) Impact Factor
- 2.9 (2023) 5 year IF
- 5.0 (2023) CiteScore (Scopus)
- Q2 CiteScore Best Quartile
- 0.465 (2023) SNIP
- 0.690 (2023) SJR
Understanding and using journal metrics
Journal metrics can be a useful tool for readers, as well as for authors who are deciding where to submit their next manuscript for publication. However, any one metric only tells a part of the story of a journal’s quality and impact. Each metric has its limitations which means that it should never be considered in isolation, and metrics should be used to support and not replace qualitative review.
We strongly recommend that you always use a number of metrics, alongside other qualitative factors such as a journal’s aims & scope, its readership, and a review of past content published in the journal. In addition, a single article should always be assessed on its own merits and never based on the metrics of the journal it was published in.
For more details, please read the Author Services guide to understanding journal metrics.
Journal metrics in brief
Usage and acceptance rate data above are for the last full calendar year and are updated annually in February. Speed data is updated every six months, based on the prior six months. Citation metrics are updated annually mid-year. Please note that some journals do not display all of the following metrics (find out why).
- Usage: the total number of times articles in the journal were viewed by users of Taylor & Francis Online in the previous calendar year, rounded to the nearest thousand.
Citation Metrics
- Impact Factor*: the average number of citations received by articles published in the journal within a two-year window. Only journals in the Clarivate Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts and Humanities Citation Index (AHCI) and the Emerging Sources Citation Index (ESCI) have an Impact Factor.
- Impact Factor Best Quartile*: the journal’s highest subject category ranking in the Journal Citation Reports. Q1 = 25% of journals with the highest Impact Factors.
- 5 Year Impact Factor*: the average number of citations received by articles in the journal within a five-year window.
- CiteScore (Scopus)†: the average number of citations received by articles in the journal over a four-year period.
- CiteScore Best Quartile†: the journal’s highest CiteScore ranking in a Scopus subject category. Q1 = 25% of journals with the highest CiteScores.
- SNIP (Source Normalized Impact per Paper): the number of citations per paper in the journal, divided by citation potential in the field.
- SJR (Scimago Journal Rank): Average number of (weighted) citations in one year, divided by the number of articles published in the journal in the previous three years.
Speed/acceptance
- From submission to first decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision. Based on manuscripts receiving a first decision in the last six months.
- From submission to first post-review decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision if it is sent out for peer review. Based on manuscripts receiving a post-review first decision in the last six months.
- From acceptance to online publication: the average (median) number of days from acceptance of a manuscript to online publication of the Version of Record. Based on articles published in the last six months.
- Acceptance rate: articles accepted for publication by the journal in the previous calendar year as percentage of all papers receiving a final decision.
For more details on the data above, please read the Author Services guide to understanding journal metrics.
*Copyright: Journal Citation Reports®, Clarivate Analytics
†Copyright: CiteScore™, Scopus
Editorial board
Senior Editors
Tsang K, Precision Biologics, Inc, National Cancer Institute, USA
Kawakami Y, Keio University School of Medicine, Tokyo, Japan
Marincola FM, Sidra Medical and Research Centre, Doha, Qatar
Wraith DC, University of Birmingham, UK
Associate Editors
Apostolopoulos V, Victoria University, Australia
Fung JJ, Cleveland Clinic Foundation, OH, USA
Puri RK, Food and Drug Administration, MD, USA
Sato N, Sapporo Medical University School of Medicine, Japan
Editorial Board
Ablin RJ, University of Arizona College of Medicine, AZ, USA
Adams S, NYU Cancer Institute, NY, USA
Alexander S, Children’s Hospital at Westmead, Australia
Bayry J, INSERM, Paris, France
Bohle B, Medical University of Vienna, Austria
Brander C, Fundació irsiCaixa, Hospital Universitari Germans Trias i Pujol, Spain
Buonaguro L, Istituto Nazionale Tumori ‘Fond. G. Pascale’, Italy
Dalgleish A, St George’s University of London, UK
Darcy PK, Peter MacCallum Cancer Centre, Australia
Griffith TS, University of Minnesota, MN, USA
Janda KD, The Scripps Research Institute, CA, USA
Jackson AM, University of Nottingham, UK
Kabelitz D, University of Kiel, Germany
Kaveri SV, INSERM, Paris, France
Kirkwood JM, University of Pittsburgh, PA, USA
Mazda O, Kyoto Prefectural University of Medicine, Japan
Platt JL, University of Michigan, MI, USA
Sasada T, Kurume University School of Medicine, Japan
Shapira MY, Hadassah-Hebrew University Medical Center, Israel
Shariat SF, Medical University Vienna, Austria
Stauss HJ, University College London, UK
Trzonkowski P, Medical University of Gdansk, Poland
Yamamura T, National Institute of Neurosicences, Tokyo, Japan
Zamvil SS, University of California San Francisco, CA, USA
Open access
Immunotherapy is a hybrid open access journal that is part of our Open Select publishing program, giving you the option to publish open access. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.
Why choose open access?
- Increase the discoverability and readership of your article
- Make an impact and reach new readers, not just those with easy access to a research library
- Freely share your work with anyone, anywhere
- Comply with funding mandates and meet the requirements of your institution, employer or funder
- Rigorous peer review for every open access article
Article Publishing Charges (APC)
If you choose to publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis.
Use our APC finder to calculate your article publishing charge
22 issues per year
Taylor & Francis make every effort to ensure the accuracy of all the information (the "Content") contained in our publications. However, Taylor & Francis, our agents (including the editor, any member of the editorial team or editorial board, and any guest editors), and our licensors, make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to, or arising out of the use of the Content. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions .
Ready to submit?
Start a new submission or continue a submission in progress
Go to submission site (link opens in a new window) Instructions for authors